Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 7681 results

  1. Prolonged-release diazoxide choline for treating Prader-Willi syndrome [ID1389]

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442

    In development [GID-TA11424] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  5. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development [GID-TA11087] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458

    Awaiting development [GID-TA11477] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232

    Awaiting development [GID-TA11230] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]

    Awaiting development [GID-TA11515] Expected publication date: 09 January 2025

    Technology appraisal guidance
    Awaiting development

  9. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    Awaiting development [GID-TA11511] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Artificial intelligence technologies to help detect fractures on X-rays in urgent care

    In development [GID-HTE10044] Expected publication date: 14 January 2025

    Health technology evaluations
    In development

  11. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development

  12. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462

    In development [GID-TA11602] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]

    In development [GID-TA10999] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Falls: assessment and prevention in older people and people 50 and over at higher risk (update)

    In development [GID-NG10228] Expected publication date: 26 March 2025

    NICE guideline
    In development

  15. Falls: assessment and prevention in older people and people 50 and over at higher risk (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 28 November 2024.

    NICE guideline
    In consultation